Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies
暂无分享,去创建一个
S. Shariat | P. Karakiewicz | G. Marvaso | B. Jereczek-Fossa | V. Schuettfort | G. Petralia | O. de Cobelli | M. Ferro | N. Fusco | F. Mistretta | N. Miura | K. Mori | A. Aydh | E. Laukhtina | G. Musi | S. Luzzago | M. Piccinelli
[1] H. G. van der Poel,et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2020, European urology.
[2] J. Yaxley,et al. 68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer , 2020, European Journal of Nuclear Medicine and Molecular Imaging.
[3] M. Brunelli,et al. Incidental prostate cancer after transurethral resection of the prostate: analysis of incidence and risk factors in 458 patients. , 2020, Minerva urologica e nefrologica = The Italian journal of urology and nephrology.
[4] D. Margolis,et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. , 2019, European urology.
[5] B. Jereczek-Fossa,et al. Confirmatory multiparametric magnetic resonance imaging at recruitment confers prolonged stay in active surveillance and decreases the rate of upgrading at follow-up , 2019, Prostate Cancer and Prostatic Diseases.
[6] V. Mirone,et al. Multiparametric Magnetic Resonance Imaging Second Opinion May Reduce the Number of Unnecessary Prostate Biopsies: Time to Improve Radiologists’ Training Program? , 2019, Clinical genitourinary cancer.
[7] U. Capitanio,et al. Temporal Trend in Incidental Prostate Cancer Detection at Surgery for Benign Prostatic Hyperplasia. , 2018, Urology.
[8] V. Mirone,et al. Multiparametric Magnetic-Resonance to Confirm Eligibility to an Active Surveillance Program for Low-Risk Prostate Cancer: Intermediate Time Results of a Third Referral High Volume Centre Active Surveillance Protocol , 2018, Urologia Internationalis.
[9] D. Margolis,et al. MRI‐Targeted or Standard Biopsy for Prostate‐Cancer Diagnosis , 2018, The New England journal of medicine.
[10] R. Cohen,et al. The Impact of Prostate Cancer Zonal Origin on Pathological Parameters at Radical Prostatectomy and Subsequent Biochemical Failure , 2017, The Journal of urology.
[11] P. Carroll,et al. Low-risk Prostate Cancer: Identification, Management, and Outcomes. , 2017, European urology.
[12] M. Parmar,et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confi rmatory study , 2018 .
[13] M. Roobol,et al. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment. , 2016, European urology.
[14] L. Weissbach,et al. Active surveillance in localized prostate cancer: comparison of incidental tumours (T1a/b) and tumours diagnosed by core needle biopsy (T1c/T2a): results from the HAROW study , 2016, BJU international.
[15] L. Weissbach,et al. Treatment of Incidental Prostate Cancer by Active Surveillance: Results of the HAROW Study , 2015, Urologia Internationalis.
[16] F. Montorsi,et al. What is the optimal definition of misclassification in patients with very low-risk prostate cancer eligible for active surveillance? Results from a multi-institutional series. , 2015, Urologic oncology.
[17] Danny Vesprini,et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Y. Choi,et al. Clinical Experiences of Incidental Prostate Cancer after Transurethral Resection of Prostate (TURP) According to Initial Treatment: A Study of a Korean High Volume Center , 2013, Yonsei medical journal.
[19] R. Manecksha,et al. Survival after incidental prostate cancer diagnosis at transurethral resection of prostate: 10-year outcomes , 2012, Irish Journal of Medical Science.
[20] J. Fütterer,et al. ESUR prostate MR guidelines 2012 , 2012, European Radiology.
[21] M. Humphreys,et al. Incidental prostate cancer revisited: Early outcomes after holmium laser enucleation of the prostate , 2011, International journal of urology : official journal of the Japanese Urological Association.
[22] Alan W Partin,et al. Active Surveillance Program for Prostate Cancer: An Update of the Johns Hopkins Experience , 2011 .
[23] J. Johansson,et al. Incidence and mortality of incidental prostate cancer: a Swedish register-based study , 2008, British Journal of Cancer.
[24] M. Peyromaure,et al. Predictive factors for progression in patients with clinical stage T1a prostate cancer in the PSA era. , 2008, European urology.
[25] G. Aus,et al. Long-term follow-up of conservatively managed incidental carcinoma of the prostate A multivariate analysis of prognostic factors , 2007, Scandinavian journal of urology and nephrology.
[26] K. Pummer,et al. Did the rate of incidental prostate cancer change in the era of PSA testing? A retrospective study of 1127 patients. , 2003, Urology.
[27] C. Wiggins,et al. Incidental detection of population-based prostate cancer incidence rates through transurethral resection of the prostate. , 2002, Urologic oncology.
[28] Y. Reinberg,et al. Long-term followup results after expectant management of stage A1 prostatic cancer. , 1991, The Journal of urology.
[29] P. Walsh,et al. Prognosis of untreated stage A1 prostatic carcinoma: a study of 94 cases with extended followup. , 1986, The Journal of urology.
[30] D. Margolis,et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. , 2016, European urology.
[31] J. Jones,et al. Probability of finding T1a and T1b (Incidental) prostate cancer during TURP has decreased in the PSA era , 2009, Prostate Cancer and Prostatic Diseases.